University of Texas MD Anderson: Combination Creates Powerful Central Memory T Cells for Cellular Therapy
March 27, 2020
March 27, 2020
HOUSTON, Texas, March 27 [TNSmedicalresearch] -- The University of Texas's MD Anderson Cancer Center issued the following news release:
* * *
- Interleukin-21 plus panobinostat re-program effector cells to a more persistent type of T cell
* * *
Treating T cells harvested from a patient with a combination of an epigenetic drug and a cytokine while expanding the cells in the lab re-programs them into a stronger T cell type that persists longer th . . .
* * *
- Interleukin-21 plus panobinostat re-program effector cells to a more persistent type of T cell
* * *
Treating T cells harvested from a patient with a combination of an epigenetic drug and a cytokine while expanding the cells in the lab re-programs them into a stronger T cell type that persists longer th . . .